Title |
G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics
|
---|---|
Published in |
American Journal of Physiology: Cell Physiology, April 2023
|
DOI | 10.1152/ajpcell.00397.2022 |
Pubmed ID | |
Authors |
Gavin P Schmitz, Bryan L Roth |
Abstract |
G protein coupled receptors (GPCRs) constitute the largest family of druggable genes in the human genome. Even though perhaps 30% of approved medications target GPCRs, they interact with only a small number of them. Here we consider whether there might be new opportunities for transformative therapeutics for neuropsychiatric disorders by specifically targeting both known and understudied GPCRs. Using psychedelic drugs which target serotonin receptors as an example, we show how recent insights into the structure, function, signaling, and cell biology of these receptors has led to potentially novel therapeutics. We next focus on the possibility that non-psychedelic 5-HT2A agonists might prove to be safe and rapidly acting antidepressants. Finally, we examine understudied and orphan GPCRs using the MRGPR-family of receptors as an example. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 10 | 32% |
Belgium | 1 | 3% |
Netherlands | 1 | 3% |
Unknown | 19 | 61% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 20 | 65% |
Scientists | 9 | 29% |
Science communicators (journalists, bloggers, editors) | 2 | 6% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 7 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 29% |
Student > Bachelor | 1 | 14% |
Unspecified | 1 | 14% |
Unknown | 3 | 43% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 2 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 14% |
Unspecified | 1 | 14% |
Unknown | 3 | 43% |